Pre-made Dusigitumab biosimilar ( Whole mAb, anti-IGF1&IGF2 therapeutic antibody) - benchmark reference antibody
Cat No.: GMP-Bios-ab-160
Anti-IGF1&IGF2 therapeutic antibody (Pre-made Dusigitumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Dusigitumab is a human monoclonal antibody designed for the treatment of cancer. It binds to IGLF2. It was developed by MedImmune, which was acquired by AstraZeneca, using Xenomouse technology licensed from Abgenix.
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Anti-IGF1&IGF2 therapeutic antibody (Pre-made Dusigitumab biosimilar,Whole mAb)|
|Highest_Clin_Trial (Jan '20)||Phase-II|
|100% SI Structure||None|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Conditions Discontinued||Breast cancer;Liver cancer;Solid tumours|